Accelerating Innovation in Drug Discovery: Comprehensive CRDMO Services by Jubilant Biosys

The global pharmaceutical industry is witnessing a rapid transformation driven by innovation, collaboration, and efficiency. As drug development becomes increasingly complex, the need for integrated scientific solutions has given rise to the CRDMO model — Contract Research, Development, and Manufacturing Organization.

Jubilant Biosys, a trusted global leader in drug discovery and development, offers end-to-end CRDMO services that seamlessly integrate discovery, development, and manufacturing under one roof. With a commitment to scientific excellence and operational flexibility, Jubilant Biosys empowers biotech and pharmaceutical partners to accelerate their pipelines across diverse therapeutic areas — including Oncology, Central Nervous System (CNS) Disorders, Pain and Inflammation, and Metabolic Disorders.

 

What Are CRDMO Services?

CRDMO Services represent an evolution of the traditional CRO (Contract Research Organization) and CMO (Contract Manufacturing Organization) models. By combining Contract Research, Contract Development, and Contract Manufacturing within a unified structure, a CRDMO delivers a seamless transition from early-stage discovery to commercial-scale production.

This model ensures:

·        Reduced timelines by eliminating handovers between multiple vendors.

·        Streamlined communication with a single scientific partner.

·        Cost-effective, flexible project management aligned with client goals.

·        High-quality outcomes through data integrity and scientific continuity.

At Jubilant Biosys, this integrated approach bridges discovery and development, enabling clients to move faster from concept to clinic — with full control, transparency, and technical rigor.

 

Therapeutic Areas of Excellence

1. Oncology: Driving Breakthroughs in Cancer Research

Cancer remains one of the most critical global health challenges. Jubilant Biosys brings deep scientific understanding and world-class infrastructure to deliver CRDMO services that accelerate oncology drug discovery and development.

From target identification and validation to preclinical studies, formulation, and manufacturing, Jubilant Biosys offers end-to-end solutions for small molecules, biologics, and Antibody-Drug Conjugates (ADCs).

Key Oncology CRDMO capabilities include:

·        High-throughput screening of novel cancer targets.

·        In-vitro and in-vivo efficacy studies.

·        Medicinal chemistry optimization for potency and safety.

·        GMP-compliant manufacturing for early and late-stage candidates.

By integrating cutting-edge biology and chemistry, Jubilant Biosys enables the creation of precision oncology therapies that deliver targeted efficacy and reduced toxicity — accelerating breakthroughs that redefine cancer care.

 

2. Central Nervous System (CNS) Disorders: Addressing the Complexity of the Brain

Developing treatments for CNS disorders such as Alzheimer’s, Parkinson’s, and depression requires a deep understanding of neurobiology and drug delivery challenges. Jubilant Biosys leverages its neuroscience expertise to deliver specialized CRDMO solutions designed to overcome barriers like blood-brain penetration and complex neuronal signaling.

Key services include:

·        Neuroreceptor binding and signaling assays.

·        In-vitro and in-vivo models for cognition, mood, and neurodegeneration.

·        PK/PD correlation and CNS-targeted formulation development.

·        GMP production with stringent quality and safety standards.

By integrating discovery biology, DMPK, and manufacturing expertise, Jubilant Biosys supports partners in developing safe, effective, and brain-penetrant CNS therapeutics that improve neurological function and quality of life.

 

3. Pain and Inflammation: Innovative Approaches to Safer Relief

Chronic pain and inflammation affect millions worldwide, but many existing therapies carry the risk of addiction or adverse side effects. Jubilant Biosys’s CRDMO services focus on the discovery and development of safer, non-opioid alternatives using advanced pharmacology, molecular biology, and chemistry.

Capabilities include:

·        Cellular assays for COX inhibition, cytokine modulation, and immune signaling.

·        Target validation for ion channels, GPCRs, and inflammatory mediators.

·        Formulation and process development for oral and injectable delivery.

·        Scalable GMP manufacturing of pain and inflammation therapeutics.

Through data-driven biology and efficient manufacturing, Jubilant Biosys helps clients create next-generation anti-inflammatory and analgesic drugs that combine efficacy with safety — addressing a major unmet medical need.

 

4. Metabolic Disorders: Precision Solutions for Global Health Challenges

The prevalence of metabolic disorders such as diabetes, obesity, and fatty liver disease continues to rise worldwide. Jubilant Biosys delivers integrated CRDMO services that combine biological understanding, chemical innovation, and scalable production to accelerate the development of novel metabolic therapies.

Key capabilities include:

·        Target discovery for key metabolic enzymes and transporters.

·        In-vitro and in-vivo models for insulin resistance, lipid metabolism, and energy regulation.

·        Medicinal chemistry optimization for efficacy and selectivity.

·        GMP-compliant synthesis and formulation for preclinical and clinical studies.

By uniting discovery and manufacturing expertise, Jubilant Biosys supports the creation of transformative metabolic therapeutics that restore balance and improve patient outcomes.

 

Why Choose Jubilant Biosys for CRDMO Services

Partnering with Jubilant Biosys offers access to a global network of scientific expertise, state-of-the-art facilities, and a proven track record of successful collaborations with top pharmaceutical companies.

Key advantages include:

·        Fully integrated discovery-to-manufacturing model ensuring faster development timelines.

·        Comprehensive therapeutic expertise across oncology, CNS, pain, and metabolic disorders.

·        Flexible engagement models — FTE-based, milestone-driven, or partnership collaborations.

·        GLP and GMP compliance ensuring quality, reproducibility, and regulatory readiness.

·        Experienced multidisciplinary teams combining chemistry, biology, and DMPK expertise.

With innovation at its core, Jubilant Biosys helps clients achieve scientific milestones efficiently and cost-effectively while maintaining the highest standards of data integrity and operational excellence.

 

Conclusion: Building the Future of Drug Discovery with CRDMO Excellence

As the pharmaceutical landscape evolves, CRDMO partnerships are redefining how new drugs are discovered, developed, and delivered to patients. With its integrated infrastructure, scientific depth, and global presence, Jubilant Biosys stands at the forefront of this transformation.

From oncology breakthroughs and CNS therapies to pain management and metabolic innovation, Jubilant Biosys’s CRDMO services deliver end-to-end support that accelerates discovery and drives clinical success.